WILMINGTON, Mass. and OKLAHOMA CITY, Feb. 29,
2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile
contract development and manufacturing organization (CDMO),
announced today a new strategic agreement with Charles River
Laboratories International, Inc. (NYSE: CRL), a global leader in
pharma services, to offer Wheeler Bio's Portable CMC® (Chemistry,
Manufacturing and Controls) platform to Charles River Laboratory
clients. The collaboration is designed to enable a swift transition
from pre-clinical stages directly to human clinical trials.
Combining Charles River's industry-leading experience in
antibody discovery services, safety, and analytics with Wheeler's
Portable CMC® platform will accelerate therapeutic discovery to
Investigational New Drug (IND) submission timelines. This umbrella
offering efficiently connects the preclinical, clinical
manufacturing, and release testing journeys, significantly reducing
the complexity of managing multiple vendor relationships.
Integrating CMC development early in discovery enables therapeutic
developers to collaborate with experts across the organizations to
utilize phase-appropriate manufacturing and analytics. The services
and expertise come together to provide a single
concept-to-commercial offering.
Wheeler Bio's mission is to solve translational challenges
inherent in advancing from discovery to CMC development and
early-clinical trial material supply. Their Portable CMC® is a
validation-ready production process which reduces technical and
regulatory risk. The organization operates the Portable
CMC® platform in Wheeler's state-of-the-art process
development labs in Oklahoma City, OK, which also houses a
CGMP facility-of-the-future including a RightSource™ quality
control testing lab. There is an additional satellite lab
in Waltham, MA featuring protein sciences and bench scale
process capabilities. Wheeler Bio provides startup biotechs
with access to a high quality, agile, affordable path to clinical
supply with thoughtfully designed, modular work packages featuring
the industry leading Leap-In Transposase® mediated gene delivery
system from ATUM for robust high titer CHO pool-based workflow
parallelization, standard analytics, and discrete CMC milestones
that align with innovators' fundraising milestones.
Jesse McCool, CEO and Co-Founder
of Wheeler Bio, stated, "Wheeler is excited to expand our
relationship with Charles River and to link with their discovery
organization. By integrating discovery CRO and CDMO
workflows, we can speed our clients' path to first-in-human trials
through better insights, thereby achieving clinical decisions
faster. Our combined sales teams look forward to co-promoting these
services for the benefit of our biotech partners and their
pipelines towards clinical impact."
Julie Frearson, Corporate Senior
Vice President, Chief Scientific Officer at Charles River,
highlighted the potential of this partnership: "We are thrilled to
provide our clients with access to Wheeler's innovative Portable
CMC® platform, which will optimize their workflows and ultimately
bring new treatments to patients faster."
About Wheeler Bio
Wheeler Bio is a biomanufacturing pioneer, founded by a team of
industry experts and strategic investors who believe a different
CDMO model is needed to help innovators reach their clinical
milestones faster. Wheeler's novel hub-and-spoke operational model,
centered in the biomanufacturing metro of Oklahoma City, and
integrated with biotechs and discovery CROs, will revolutionize the
speed of drug development. Wheeler Bio's technology platform,
Portable CMC® simplifies the path between drug discovery and
clinical manufacturing by providing a new bridge for translating
discoveries to first-in-human trials. Innovators benefit from
increased momentum during technology transfer, shorter timelines,
reduced risk, and lower costs. Additional information can be
obtained by visiting www.wheelerbio.com or by following
Wheeler Bio on LinkedIn.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
About ATUM
ATUM is a fully integrated Californian based CRDO (Contract
Research & Development Organization) biotechnology industry
leader. ATUM, over the last two decades, has served life science
researchers by delivering high quality services including but not
limited to Gene Design and Gene Synthesis, Protein Engineering,
Protein Production, Leap-In Transposase®, Cell Line Development,
and Master Cell Banking (MCB). With a state-of-the-art
machine learning platform, proprietary algorithms, and a fully
integrated Laboratory Information Management System (LIMS), ATUM
provides platforms and services that span from virtual sequence to
manufacturing ready MCB. ATUM has a culture of continuous
commitment to innovation where solutions are built on bioengineered
solutions to bring speed to market, supporting the biotech
ecosystem from pre-clinical research through IND and beyond.
Contact us today for more information at www.atum.bio.
For Further Information:
Wheeler Bio, Inc.
Contact: Jaden Polston
jpolston@wheelerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/wheeler-bio-seals-agreement-with-charles-river-to-offer-portable-cmc-to-discovery-clients-to-accelerate-their-journey-to-first-in-human-use-302075145.html
SOURCE Wheeler Bio